174 related articles for article (PubMed ID: 38247197)
1. NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6C
Ying K; Xin W; Xu Y; Lv D; Zhu H; Li Y; Xu W; Yan C; Li Y; Cheng H; Chen E; Ma G; Zhang X; Ke Y
Adv Sci (Weinh); 2024 Apr; 11(13):e2308166. PubMed ID: 38247197
[TBL] [Abstract][Full Text] [Related]
2. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
3. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of leukemia-associated SHP2
Sun X; Ren Y; Gunawan S; Teng P; Chen Z; Lawrence HR; Cai J; Lawrence NJ; Wu J
Leukemia; 2018 May; 32(5):1246-1249. PubMed ID: 29568093
[No Abstract] [Full Text] [Related]
5. Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients.
Fernández DI; Diender M; Hermida-Nogueira L; Huang J; Veiras S; Henskens YMC; Te Loo MWM; Heemskerk JWM; Kuijpers MJE; García Á
Thromb Res; 2023 Aug; 228():105-116. PubMed ID: 37302266
[TBL] [Abstract][Full Text] [Related]
6. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
7. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human granulocyte colony-stimulating factor enhanced the resolution of venous thrombi.
Chen YK; Jiang XM; Gong JP
J Vasc Surg; 2008 May; 47(5):1058-65. PubMed ID: 18358673
[TBL] [Abstract][Full Text] [Related]
9. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
10. Combined administration of SHP2 inhibitor SHP099 and the α7nAChR agonist PNU282987 protect mice against DSS‑induced colitis.
Xiao J; Zhang G; Gao S; Shen J; Feng H; He Z; Xu C
Mol Med Rep; 2020 Sep; 22(3):2235-2244. PubMed ID: 32705242
[TBL] [Abstract][Full Text] [Related]
11. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
13. Ly6CLo Monocyte/Macrophages are Essential for Thrombus Resolution in a Murine Model of Venous Thrombosis.
Kimball AS; Obi AT; Luke CE; Dowling AR; Cai Q; Adili R; Jankowski H; Schaller M; Holinstadt M; Jaffer FA; Kunkel SL; Gallagher KA; Henke PK
Thromb Haemost; 2020 Feb; 120(2):289-299. PubMed ID: 31887775
[TBL] [Abstract][Full Text] [Related]
14. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
15. Novel PROTACs for degradation of SHP2 protein.
Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of the injectable thermosensitive hydrogel loaded with SHP099 on intervertebral disc degeneration.
Wang J; Huang L; Huang Y; Jiang Y; Zhang L; Feng G; Liu L
Life Sci; 2021 Feb; 266():118891. PubMed ID: 33310047
[TBL] [Abstract][Full Text] [Related]
17. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
18. Endogenous Uteroglobin as Intrinsic Anti-inflammatory Signal Modulates Monocyte and Macrophage Subsets Distribution Upon Sepsis Induced Lung Injury.
Janicova A; Becker N; Xu B; Wutzler S; Vollrath JT; Hildebrand F; Ehnert S; Marzi I; Störmann P; Relja B
Front Immunol; 2019; 10():2276. PubMed ID: 31632392
[TBL] [Abstract][Full Text] [Related]
19. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction.
Frantz S; Hofmann U; Fraccarollo D; Schäfer A; Kranepuhl S; Hagedorn I; Nieswandt B; Nahrendorf M; Wagner H; Bayer B; Pachel C; Schön MP; Kneitz S; Bobinger T; Weidemann F; Ertl G; Bauersachs J
FASEB J; 2013 Mar; 27(3):871-81. PubMed ID: 23159933
[TBL] [Abstract][Full Text] [Related]
20. SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations.
Pandey R; Ramdas B; Wan C; Sandusky G; Mohseni M; Zhang C; Kapur R
J Clin Invest; 2019 Dec; 129(12):5468-5473. PubMed ID: 31682240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
